# An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma

> **NCT00787410** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 23 (actual)

## Conditions studied

- Mesothelioma

## Interventions

- **DRUG:** ZD1839

## Key facts

- **NCT ID:** NCT00787410
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2012-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00787410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00787410, "An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00787410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*